form_8k-041002
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report: April 10, 2002
Medix Resources, Inc.
(Exact name of registrant as specified in its charter)
Colorado 0-24768 84-1123311
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
420 Lexington Avenue, Suite 1830 , New York, NY 10170
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 697-2509
Item 5. Other Events. Press release dated April 10, 2002, announcing
completion of Cymedix III.
Exhibits
99.1 Copy of Press Release
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDIX RESOURCES, INC.
Date: April 10, 2002 By: Gary L. Smith
Executive Vice President and
Chief Financial Officer
Exhibit 99.1
News Release
CONTACT: Gary Smith
(212) 697-2509
(212) 681-9817 (fax)
Andrew Brown
(718) 323-7424
MEDIX RESOURCES ANNOUNCES COMPLETION OF CYMEDIX III
------
NEW YORK, April 10th - Medix Resources, Inc. (AMEX: MXR) today announced
that its latest version of its Cymedix(R)product suite is now complete, and is
available to be deployed in target markets throughout the U.S. "Cymedix(R)III
represents a milestone in production-ready eHealth technology that enables
frictionless medicine, thus providing effortless prescription management, lab
order entry and results and critical administrative transactions.", stated
Louis Hyman, Chief Technology Officer of Medix.
Utilizing the proprietary Cymedix(R)Universal Interface ("CUI"), Cymedix(R)
III is positioned to be easily adopted amongst targeted physician practices.
"The CUI's unique power to seamlessly integrate critical data existing within
the physician's practice management system, with the data existing at PBM,
health plans and lab companies, is a cornerstone of our formula for physician
adoption". "Transparently, Cymedix(R)III does the heavy lifting required for
physicians and their staffs to quickly realize efficiencies. We believe this is
the key to driving adoption of the Cymedix(R)III product suite and ensuring its
use over the long-term", continued Hyman.
Cymedix(R)III is designed to allow for rapid deployment and accelerated
utilization among physician practices. The technology features encrypted
transaction modules that are designed to exceed current and proposed HIPAA
regulations relating to the privacy and security of data transmissions.
Cymedix(R)III enables physicians to automate virtually all frequently occurring
clinical and administrative tasks - using a single technology platform. As a
result, physician and their staff can leverage a highly efficient means of
communication with health plans, Labs and PBM's.
"I cannot envision a better launching-pad for future product enhancements
than the fully scalable, device-neutral and robust integration capabilities
that form the foundation technologies of Cymedix(R)III. Though we are quite
pleased with the positive evolution of our technologies, our technology team
maintains a forward looking development plan, which should allow continued
advancement of our product suite and expand upon our product's importance
within the physicians office", concluded John Prufeta, Medix's CEO and
President.
About Medix Resources, Inc.
Medix Resources, Inc., through its wholly owned subsidiary Cymedix Lynx
Corporation, is the developer and provider of the Cymedix(R)suite of fully
secure, Internet based transaction software products, that enable
communication of high value added healthcare information among physician
offices, hospitals, health management organizations and health insurance
companies. Additional information about Medix Resources and its products and
services can be found by visiting its Web sites, WWW.MEDIXRESOURCES.COM and
WWW.CYMEDIX.COM, or by calling (800) 326-8773.
# # #
Information in this press release contains forward-looking statements that
involve risks and uncertainties that might adversely affect Medix's operating
results in the future to a material degree. Such risks and uncertainties
include, without limitation, the ability of Medix to raise capital to finance
the development of its software products, the effectiveness and the
marketability of those products, the ability of the Company to protect its
proprietary information, and the establishment of an efficient corporate
operating structure as the Company grows. These and other risks and
uncertainties are presented in detail in the Company's Amended Form 10-K for
2001, which was filed with the Securities and Exchange Commission on April 5,
2002. This information is available from the SEC or the Company.